Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Intestinal2466 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A09314 | 31793675 | J Food Biochem | Ganoderma polysaccharide and chitosan synergistically ameliorate lipid metabolic disorders and modulate gut microbiota composition in high fat diet-fed golden hamsters. | 2019 | Details |
| A09316 | 31793324 | Nutr Hosp | Immunonutritional contribution of gut microbiota to fatty liver disease. | 2020 | Details |
| A09323 | 31790895 | Phytomedicine | Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway. | 2019 | Details |
| A09332 | 31788011 | Nutr Metab (Lond) | Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE-/- mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation. | 2019 | Details |
| A09342 | 31784293 | Arch Pediatr | Feeding problems and gastrointestinal diseases in Down syndrome. | 2019 | Details |
| A09347 | 31782595 | Liver Int | Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis. | 2019 | Details |
| A09361 | 31777896 | Food Funct | Attenuation of metabolic syndrome in the ob/ob mouse model by resistant starch intervention is dose dependent. | 2019 | Details |
| A09364 | 31777425 | J Clin Biochem Nutr | Plasma quercetin metabolites are affected by intestinal microbiota of human microbiota-associated mice fed with a quercetin-containing diet. | 2019 | Details |
| A09383 | 31767938 | Sci Rep | Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. | 2019 | Details |
| A09402 | 31759125 | Peptides | The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). | 2019 | Details |
| A09418 | 31757631 | Nutr Res | Steatosis and gut microbiota dysbiosis induced by high-fat diet are reversed by 1-week chow diet administration. | 2019 | Details |
| A09432 | 31752378 | Nutrients | Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? | 2019 | Details |
| A09443 | 31746883 | Food Funct | Artemisia sphaerocephala Krasch polysaccharide prevents hepatic steatosis in high fructose-fed mice associated with changes in the gut microbiota. | 2019 | Details |
| A09447 | 31745030 | Indian J Med Microbiol | Gut microbiota and its mysteries. | 2020 | Details |
| A09472 | 31731192 | Biomed Pharmacother | Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease. | 2019 | Details |
| A09481 | 31727922 | Sci Rep | Fecal microbiome signatures of pancreatic cancer patients. | 2019 | Details |
| A09484 | 31726978 | BMC Genomics | Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. | 2019 | Details |
| A09485 | 31726747 | Diseases | Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? | 2019 | Details |
| A09493 | 31723265 | Nature | Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. | 2019 | Details |
| A09502 | 31717860 | Cells | The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. | 2019 | Details |
| A09527 | 31707624 | Rev Endocr Metab Disord | Dietary lipids, gut microbiota and lipid metabolism. | 2019 | Details |
| A09530 | 31706246 | Environ Toxicol Pharmacol | Microcystin exposure worsens nonalcoholic fatty liver disease associated ectopic glomerular toxicity via NOX-2-MIR21 axis. | 2019 | Details |
| A09551 | 31696774 | Gut Microbes | Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. | 2019 | Details |
| A09575 | 31689910 | Nutrients | The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. | 2019 | Details |
| A09594 | 31682518 | Endocr Pract | CLINICAL PRACTICE GUIDELINES FOR THE PERIOPERATIVE NUTRITION, METABOLIC, AND NONSURGICAL SUPPORT OF PATIENTS UNDERGOING BARIATRIC PROCEDURES - 2019 UPDATE: COSPONSORED BY AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY, THE OBESITY SOCIETY, AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY, OBESITY MEDICINE ASSOCIATION, AND AMERICAN SOCIETY OF ANESTHESIOLOGISTS - EXECUTIVE SUMMARY. | 2019 | Details |
| A09644 | 31661720 | Hepatol Res | Changes of gut microbiota during silybin-mediated treatment of high-fat diet-induced non-alcoholic fatty liver disease in mice. | 2020 | Details |
| A09653 | 31657510 | Mol Nutr Food Res | The Buckwheat Iminosugar d-Fagomine Attenuates Sucrose-Induced Steatosis and Hypertension in Rats. | 2019 | Details |
| A09666 | 31653116 | Int J Mol Sci | The Positive Effects of Grifola frondosa Heteropolysaccharide on NAFLD and Regulation of the Gut Microbiota. | 2019 | Details |
| A09670 | 31652636 | Cells | MicroRNA-29a Suppresses CD36 to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice. | 2019 | Details |
| A09757 | 31622696 | J Hepatol | The gut-liver axis in liver disease: Pathophysiological basis for therapy. | 2019 | Details |
| A09795 | 31607647 | Ann Hepatol | Validation of original, expanded Baveno VI, and stepwise & platelet-MELD criteria to rule out varices needing treatment in compensated cirrhosis from various etiologies. | 2019 | Details |
| A09809 | 31602167 | World J Gastroenterol | Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history. | 2019 | Details |
| A09811 | 31601229 | Trials | Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. | 2019 | Details |
| A09814 | 31600750 | Digestion | Rodent Models of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09818 | 31599067 | Mol Nutr Food Res | Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis. | 2019 | Details |
| A09840 | 31594095 | Zhonghua Gan Zang Bing Za Zhi | [Study on the correlation between small intestinal dendritic cells and non-alcoholic fatty liver disease in mice]. | 2019 | Details |
| A09858 | 31589177 | Curr Opin Clin Nutr Metab Care | Vitamin D and nonalcoholic fatty liver disease. | 2019 | Details |
| A09891 | 31573042 | Int J Mol Med | Fatty liver and alteration of the gut microbiome induced by diallyl disulfide. | 2019 | Details |
| A09892 | 31572482 | Arch Med Sci | Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. | 2019 | Details |
| A09901 | 31568518 | PLoS One | Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome. | 2019 | Details |
| A09902 | 31567712 | Eur J Gastroenterol Hepatol | Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. | 2020 | Details |
| A09924 | 31558860 | World J Gastroenterol | Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. | 2019 | Details |
| A09925 | 31558417 | Ann Hepatol | Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. | 2019 | Details |
| A09929 | 31555950 | Gastric Cancer | Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer. | 2019 | Details |
| A09930 | 31555865 | Pediatr Surg Int | Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome. | 2019 | Details |
| A09932 | 31555219 | Front Endocrinol (Lausanne) | Gut Dysfunction and Non-alcoholic Fatty Liver Disease. | 2019 | Details |
| A09935 | 31554391 | Gut Liver | The Role of Intestinal Fungi and Its Metabolites in Chronic Liver Diseases. | 2020 | Details |
| A09949 | 31547555 | Nutrients | Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors. | 2019 | Details |
| A09952 | 31545283 | Biomed Pharmacother | Gypenosides improve the intestinal microbiota of non-alcoholic fatty liver in mice and alleviate its progression. | 2019 | Details |
| A09957 | 31543676 | World J Gastroenterol | Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. | 2019 | Details |
| A09960 | 31543403 | Cell Metab | Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. | 2019 | Details |
| A09973 | 31539420 | PLoS One | Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits. | 2019 | Details |
| A10039 | 31517324 | J Gastrointestin Liver Dis | Effects of Dietary Intervention on Gut Microbiota and Metabolic-Nutritional Profile of Outpatients with Non-Alcoholic Steatohepatitis: a Randomized Clinical Trial. | 2019 | Details |
| A10045 | 31515740 | Hepatol Int | Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. | 2019 | Details |
| A10058 | 31506421 | Exp Mol Med | Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. | 2019 | Details |
| A10060 | 31505802 | Nutrients | Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models. | 2019 | Details |
| A10092 | 31491513 | Int J Biol Macromol | MDG-1, an Ophiopogon polysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis. | 2019 | Details |
| A10095 | 31488310 | Rev Gastroenterol Mex (Engl Ed) | Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver. | 2019 | Details |
| A10110 | 31480575 | Biomolecules | Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice. | 2019 | Details |
| A10144 | 31470288 | Nutr Res | Gnotobiotic mice inoculated with Firmicutes, but not Bacteroidetes, deteriorate nonalcoholic fatty liver disease severity by modulating hepatic lipid metabolism. | 2019 | Details |
| A10146 | 31470068 | J Hepatol | The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. | 2019 | Details |
| A10189 | 31442319 | Hepatology | Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. | 2020 | Details |
| A10215 | 31428351 | Food Sci Nutr | Lactobacillus paracasei Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease. | 2019 | Details |
| A10233 | 31419514 | J Hepatol | Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. | 2019 | Details |
| A10255 | 31409765 | Exp Mol Med | A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. | 2019 | Details |
| A10323 | 31388096 | Int J Obes (Lond) | Circulating microbiota-derived metabolites: a "liquid biopsy? | 2019 | Details |
| A10330 | 31387054 | Phytomedicine | The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. | 2019 | Details |
| A10338 | 31384531 | Acta Pharm Sin B | Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. | 2019 | Details |
| A10339 | 31384519 | Biosci Microbiota Food Health | The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. | 2019 | Details |
| A10351 | 31379412 | J Clin Biochem Nutr | Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice. | 2019 | Details |
| A10364 | 31373710 | Aliment Pharmacol Ther | Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. | 2019 | Details |
| A10368 | 31372513 | Commun Biol | Ability of prebiotic polysaccharides to activate a HIF1α-antimicrobial peptide axis determines liver injury risk in zebrafish. | 2019 | Details |
| A10373 | 31367159 | World J Gastroenterol | Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis via gut microbiota. | 2019 | Details |
| A10407 | 31349604 | Nutrients | Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). | 2019 | Details |
| A10408 | 31349549 | J Clin Med | Nutrition in Gastrointestinal Disease: Liver, Pancreatic, and Inflammatory Bowel Disease. | 2019 | Details |
| A10413 | 31345778 | Lancet Gastroenterol Hepatol | Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. | 2019 | Details |
| A10427 | 31341422 | Mediators Inflamm | Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10451 | 31332389 | Nat Med | Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. | 2019 | Details |
| A10465 | 31325638 | Biochim Biophys Acta Mol Cell Biol Lipids | Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. | 2019 | Details |
| A10473 | 31322321 | Mol Nutr Food Res | A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. | 2019 | Details |
| A10510 | 31308634 | Drug Des Devel Ther | The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease. | 2019 | Details |
| A10516 | 31306673 | Toxicol Appl Pharmacol | Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. | 2019 | Details |
| A10546 | 31293341 | World J Gastroenterol | Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease. | 2019 | Details |
| A10553 | 31292380 | Intern Med | High Prevalence of Autoimmune Gastritis in Patients with Nonalcoholic Steatohepatitis. | 2019 | Details |
| A10554 | 31292182 | BMJ Open | Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study. | 2019 | Details |
| A10568 | 31288283 | Z Gastroenterol | [Microbiome & NASH - partners in crime driving progression of fatty liver disease]. | 2019 | Details |
| A10580 | 31281460 | Exp Ther Med | Aged garlic extract ameliorates fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance. | 2019 | Details |
| A10611 | 31272028 | J Nutr Biochem | 1-Deoxynojirimycin improves high fat diet-induced nonalcoholic steatohepatitis by restoring gut dysbiosis. | 2019 | Details |
| A10614 | 31271251 | Mol Nutr Food Res | Diet Consisting of Balanced Yogurt, Fruit, and Vegetables Modifies the Gut Microbiota and Protects Mice against Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10617 | 31269941 | BMC Complement Altern Med | Qianggan extract improved nonalcoholic steatohepatitis by modulating lncRNA/circRNA immune ceRNA networks. | 2019 | Details |
| A10619 | 31269758 | Mar Drugs | Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. | 2019 | Details |
| A10620 | 31269076 | PLoS One | Microbial and metabolomic remodeling by a formula of Sichuan dark tea improves hyperlipidemia in apoE-deficient mice. | 2019 | Details |
| A10638 | 31258623 | Therap Adv Gastroenterol | Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. | 2019 | Details |
| A10647 | 31255652 | Gastroenterology | Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10657 | 31251379 | JAMA Netw Open | Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis. | 2019 | Details |
| A10686 | 31236687 | Handb Exp Pharmacol | Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease. | 2019 | Details |
| A10726 | 31219825 | Curr Opin Clin Nutr Metab Care | Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions? | 2019 | Details |
| A10731 | 31219051 | JMIR Res Protoc | Diet-Induced Alteration of Microbiota and Development of Obesity, Nonalcoholic Fatty Liver Disease, and Diabetes: Study Protocol of a Prospective Study. | 2019 | Details |
| A10733 | 31217465 | Sci Rep | Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10751 | 31210034 | Diabetes Metab J | Understanding Bile Acid Signaling in Diabetes: From Pathophysiology to Therapeutic Targets. | 2019 | Details |